HEMOGENYX PHARMACEUTICALS PLC

Director's Dealing • Jan 31, 2020

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4977B

Hemogenyx Pharmaceuticals PLC

31 January 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has been advised that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), purchased 257,069 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.945p per share. Following this transaction, Mr Wright now has a total beneficial interest in 1,097,405 Ordinary Shares, representing approximately 0.28 per cent of the Company's issued share capital as enlarged by the placing announced on 30 January 2020.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Andrew Wright

b)

Position/status

Financial Controller and Company Secretary/PDMR (non-board)

c)

Initial notification/

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of 1p of Hemogenyx Pharmaceuticals plc

Identification code GB00BYX3WZ24

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
GBP £0.01945	257,069

d)

Aggregated information

-     Aggregated volume

-     Price

Price(s)	Volume(s)
GBP £4,999.99	257,069

e)

Date of the transaction

30 January 2020

f)

Place of the transaction

London Stock Exchange

XLON

Enquiries:

Hemogenyx Pharmaceuticals plc	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries
Lowell Goodman	Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHGZGFMRGDGGZM